Inflammation
When OSE Immunotherapeutics' board ousted CEO Nicolas Poirier in October 2025, it handed his successor a clear mandate: spend less, partner sooner and stop asking shareholders to wait.
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
Positive results from a randomized study in healthy volunteers mark a key milestone for Alvotech’s proposed Entyvio rivals AVT80 and AVT16.
The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.
The company’s approach leverages mPGES-1 inhibition to target both inflammation-related pain and lesion load. It is moving into a Phase II trial.
How the seven-year-old biotech is building an industry-leading platform that is breaking the molecular glue dogma and could transform drug discovery.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
Arrotex has entered into a strategic partnership with Celltrion Healthcare Australia to launch two first-to-market biosimilar medicines in Australia. These biosimilars, which treat chronic inflammatory conditions, are now listed on the PBS and available through pharmacies.
A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.
CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
One Phase III trial hits but a second study misses by a mile.